Actually, EZH2 has been recognised as an oncogene in several types of tumors, such as breast cancer, prostate cancer, bladder cancer and oral squamous cell carcinoma, which makes EZH2 a potential biomarker in tumors10, 11, 12, 13. This evidence concerns the gene EZH2 and urinary bladder cancer.